{"product_id":"bysi-bcg-matrix","title":"(BYSI) BeyondSpring Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BeyondSpring Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, research, and capital allocation. The page already shows a real preview of the actual report content, so you can review the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlinabulin 2 Phase III programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc.'s Plinabulin 2 Phase III programs are its most mature assets, with Phase III development in chemotherapy-induced neutropenia and advanced NSCLC. That makes them the clearest Star fit in the BCG Matrix, since they sit closest to value creation and possible commercialization. The two late-stage shots give BeyondSpring Inc. the strongest near-term pipeline upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemotherapy-induced neutropenia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChemotherapy-induced neutropenia is a Star for BeyondSpring Inc.: it is one of the company’s lead registrational settings and addresses a large oncology supportive-care need, with febrile neutropenia risk often around 10% to 20% in higher-risk regimens. If approved, it would be BeyondSpring Inc.’s most advanced path to commercial relevance. In this market, even modest uptake can matter because prevention can reduce costly hospital stays and treatment delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced NSCLC is a Phase III bet in a cancer type that makes up about 85% of all lung cancers, so the addressable market is huge and still growing. It is one of BeyondSpring Inc.’s highest-stakes assets, because late-stage success can lift both clinical credibility and valuation. If it wins, it could materially strengthen the pipeline and improve partnering odds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlinabulin lead asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePlinabulin is BeyondSpring Inc.'s flagship molecule and the main value driver in its late-stage pipeline, so the Stars bucket fits best. Its lead role centers on oncology, where the asset anchors the rest of the portfolio and shapes most of the pipeline’s upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFlagship asset: Plinabulin\u003c\/li\u003e\n\u003cli\u003eMain late-stage value driver\u003c\/li\u003e\n\u003cli\u003ePortfolio built around it\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLate-stage immuno-oncology positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePlinabulin sits in late-stage immuno-oncology, with Phase 3 work that targets high-growth cancer care. Its combo strategy with checkpoint inhibitors ties it to a market led by Merck’s Keytruda, which posted $29.5 billion in 2024 sales, so the asset has clear \"Star\" traits in BeyondSpring Inc.'s BCG view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePhase 3 oncology pipeline\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBuilt for checkpoint inhibitor combos\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAnchored to a $29.5B category leader\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyondSpring’s Phase III Plinabulin Programs Drive Its Biggest Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc.’s Stars are Plinabulin’s Phase III programs, because they are the company’s closest shots at commercialization and the main value driver in the pipeline. Chemotherapy-induced neutropenia and advanced NSCLC give BeyondSpring Inc. late-stage upside in large oncology markets, with NSCLC making up about 85% of lung cancers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlinabulin in CIN\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003eLead registrational path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlinabulin in advanced NSCLC\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003eLarge, growing cancer market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBeyondSpring’s BCG Matrix maps its pipeline to spot stars, question marks, cash needs, and divestible dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBeyondSpring Inc. BCG Matrix: a one-page quadrant view that quickly highlights priorities and reduces analysis clutter\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for BeyondSpring Inc. that speeds due diligence and supports smarter decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of year-end 2025, BeyondSpring Inc. remains a clinical-stage company, so it still has 0 approved products and no mature franchise to generate steady cash. That leaves the Cash Cow quadrant effectively empty, with no product sales base to fund growth. In BCG terms, the company has not yet reached the stage where one asset can be milked for cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 marketed brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc. has 0 marketed brands, so it has no Cash Cow asset to harvest in the BCG Matrix. With no approved oncology product on sale, there is no established market share or stable product revenue to support cash flow. That leaves revenue tied to future trial, regulatory, and launch success rather than current brand sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 recurring product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc. shows 0 recurring product sales, so there is no disclosed product-sales engine today. The Company does not yet generate steady operating cash from commercial drugs, which keeps the cash-cow profile absent. In BCG terms, this remains a pipeline story, not a cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 royalty streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring Inc. shows 0 royalty streams, so there is no disclosed royalty-based cash cow to offset R and D burn. In its latest filings, the Company’s income mix remains centered on research spending and financing, not mature product sales or recurring legacy income. That leaves cash flow highly dependent on capital access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo disclosed royalty-bearing asset\u003c\/li\u003e\n\u003cli\u003eNo low-growth legacy income base\u003c\/li\u003e\n\u003cli\u003eCash tied to R and D funding\u003c\/li\u003e\n\u003cli\u003eHigher dilution and financing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e0 mature franchises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring has 0 mature, low-growth franchises, so there is no true Cash Cow in its BCG mix. The company is still centered on development-stage assets, not on a stable, cash-generating business line. That means cash flow still depends on funding and clinical progress, not on a mature product base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 mature franchises\u003c\/li\u003e\n\u003cli\u003eDevelopment-stage pipeline only\u003c\/li\u003e\n\u003cli\u003eNo Cash Cow yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyondSpring Has No Cash Cow Business in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of year-end 2025, BeyondSpring Inc. has no Cash Cow business: 0 approved products, 0 marketed brands, and 0 recurring product sales. Revenue still depends on R and D funding and financing, not on mature, low-growth assets. So the Cash Cow quadrant stays empty.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed brands\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring sales\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBeyondSpring Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe BeyondSpring Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No placeholders, no watermarks, and no demo content—just the full, ready-to-use report. You can download it immediately and use it for analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 divestible commercial units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc. has 0 divestible commercial units, because it has no approved commercial product line to carve out. That cuts the classic Dog profile of low share and low growth in a mature market. As of FY2025, the portfolio stayed mostly developmental, so weak cash-generating assets are not the issue here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 established market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring has no sold product category with market share, so there is no stable commercial base to defend. As of its latest 2025 filings, the Company still lacked product revenue from approved sales, which keeps this unit in the Dog bucket as a placeholder rather than a revenue engine. In BCG terms, zero share means weak pricing power, thin scale, and little cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle asset concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc. is highly concentrated in plinabulin, so the portfolio has little cushion if late-stage data or FDA outcomes weaken. In 2024, the Company still had no approved product sales, which keeps the asset tied to binary trial risk. A narrow base like this can act like a Dog if it never turns into revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e3 preclinical immune agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring Inc.’s 3 preclinical immune agents fit the Dogs bucket: they are still far from approval, so they do not generate near-term revenue.\u003c\/p\u003e\n\u003cp\u003eThese programs can still absorb R\u0026amp;D cash and management time, while the company waits through long, costly testing cycles before any sales are possible.\u003c\/p\u003e\n\u003cp\u003eThat makes them harder to sustain when biotech funding is tight and investors favor later-stage assets with clearer data and shorter paths to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 assets, no near-term sales\u003c\/li\u003e\n\u003cli\u003eHigh R\u0026amp;D drag, low cash return\u003c\/li\u003e\n\u003cli\u003eFunding risk rises in weak markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCorporate cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring Inc. sits in Dogs because clinical-stage work burns cash before sales begin. With no approved product revenue, R\u0026amp;D and trial spend stay a structural drag on value, and the latest reported filings still show the business funding operations from cash on hand rather than product sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trials need steady cash\u003c\/li\u003e\n\u003cli\u003eNo approved products, no sales cushion\u003c\/li\u003e\n\u003cli\u003eBurn rate keeps pressure on value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyondSpring’s FY2025 Dog Assets: No Sales, All Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc. has no approved product sales in FY2025, so its Dog exposure is not a mature cash cow but a set of cash-draining, low-share assets. The Company still funds operations from cash on hand, not product revenue.\u003c\/p\u003e\n\u003cp\u003eIts 3 preclinical immune agents also sit in the Dog bucket because they are too early to generate near-term sales. That leaves R\u0026amp;D spend high and cash return near zero.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved product revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical immune agents\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial base\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlinabulin plus nivolumab in NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePlinabulin plus nivolumab is a question mark: NSCLC makes up about 85% of lung cancers, but this combo is still exploratory and has no commercial share yet.\u003c\/p\u003e\n\u003cp\u003eThe space is crowded and growing, with PD-1\/PD-L1 drugs already standard care and nivolumab a proven anchor in immuno-oncology.\u003c\/p\u003e\n\u003cp\u003eTo move up, BeyondSpring Inc. needs clear clinical proof that this pairing improves outcomes enough to win uptake and price premium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlinabulin plus nivolumab plus ipilimumab in SCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePlinabulin plus nivolumab plus ipilimumab is a Question Mark for BeyondSpring Inc. in SCLC: the market is large but the science is still early. SCLC makes up about 10% to 15% of lung cancers, and the 5-year relative survival rate is about 7%, so any win could be meaningful.\u003c\/p\u003e\n\u003cp\u003eBut the program is still experimental, and success depends on strong clinical data, not just a good mechanism. If trial results do not show clear benefit, the asset stays high-risk and hard to value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlinabulin plus PD 1 or PD L1 antibodies and radiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePlinabulin plus PD-1 or PD-L1 antibodies and radiation could push BeyondSpring into larger oncology combo use cases. The PD-1\/PD-L1 class already drives more than $50B in annual sales, so the market is big, but plinabulin still has low share and no clear late-stage win yet. That makes it a classic high-potential, low-share Question Mark, with upside tied to clean clinical data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e3 preclinical small molecule immune agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring Inc.’s 3 preclinical small molecule immune agents are clear Question Marks in the BCG matrix: they sit at the earliest stage, so there is no human clinical validation yet. As preclinical assets, their value is still theoretical, but they could matter if one program shows strong safety and efficacy signals. For now, they are high-upside, high-risk pipeline options, not proven revenue drivers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 assets, all preclinical\u003c\/li\u003e\n\u003cli\u003eNo clinical data yet\u003c\/li\u003e\n\u003cli\u003eHighest risk, possible upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProprietary drug development platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyondSpring Inc.'s proprietary drug development platform fits a Question Mark: it can create future pipeline assets, but it has no direct commercial market share or recurring product sales today. In its latest public filings, BeyondSpring reported no product revenue, so the platform is still an option on future drugs, not a cash generator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFuture pipeline upside\u003c\/li\u003e\n\u003cli\u003eNo current market share\u003c\/li\u003e\n\u003cli\u003eNo direct cash flow today\u003c\/li\u003e\n\u003cli\u003eStrategic, but high-risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyondSpring’s High-Risk Pipeline Hinges on Clinical Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeyondSpring Inc.'s Question Marks are all early, high-risk bets with no commercial share yet. Plinabulin combos in NSCLC and SCLC sit in crowded oncology markets, while the 3 preclinical immune agents and the drug platform remain unproven. The upside is real, but only clear clinical data can lift value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlinabulin + nivolumab\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eNSCLC, no share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlinabulin + nivolumab + ipilimumab\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eSCLC, early\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3 small molecules\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234097897737,"sku":"bysi-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bysi-bcg-matrix.webp?v=1785713989","url":"https:\/\/dcfanalyst.com\/products\/bysi-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}